Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EGL 001

Next Previous
Drug Profile

EGL 001

Alternative Names: EGL-001

Latest Information Update: 19 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Egle Therapeutics
  • Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 2 inhibitors; Regulatory T-lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 25 Apr 2025 Pharmacodynamics and pharmacokinetics data from preclinical studies in Solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 27 Sep 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (IV) (NCT06622486)
  • 27 Sep 2024 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in France (IV) (NCT06622486)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top